Canada markets close in 3 hours 26 minutes

REGENXBIO Inc. (RGNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
38.34+0.66 (+1.75%)
As of 12:34PM EST. Market open.
Sign in to post a message.
  • h
    happy
    Waiting for $56
  • A
    Allen
    Hear ye, hear ye...long time shareholder here and very bullish! I've held a position in the stock for several years now and never gave up. But, I firmly believe we are now at an inflection point and my money backs up my thoughts. Putting it on record that as of 11/11/20 I am currently holding 10,000 shares and might go to 15-20K in the near future. Also am holding 40K CLSD< but have has been as high as 100K shares. My thesis, the future value of Zolgensma royalties provide a floor on the stock and revenues are growing while their royalty rate will widen. Other licensee firms are starting to pick up and in the readings, typically their main drivers are the RGNX-licensed therapies. WET-AMD is icing on the cake and would be a grand-slam homerun. Today the company market cap is $1.2B. Remove cash/mkt securities plus the 80MM due from NVS. We also have equity in PRVL and the newly created firm (referenced in the press release) plus a few other upcoming items of momentum/IND as well as a manufacturing facility in production 21/22. Seems like a no-brainer and IMO, patience will be greatly rewarded. There, now I sound like Kroptie! To Max who said this company is an oddball - you are correct 100%. That is when you step up bigtime and buy lots and lots of shares. Once it's not an oddball, it's too late!
  • J
    Joe
    Dec 3rd should a big day for RGNX . either diving or soaring
  • P
    Paul
    Nice trend from $28 to $38....
    Forgot I have a small position.
  • M
    Max
    This company is a total oddball. It's a biotech that...wait for it...makes money. Not enough to fund all their initiatives, but still, it has a royalty stream which is high-margin income.

    What is not to like here?

    The market is weird.
  • s
    six2one
    Have you guys noticed how they are buying without drawing attention to it. slowly but surly
  • h
    happy
    Need $56
  • R
    Rico D
    After the bell today, Novartis reported $291 million in 3rd quarter global Zolgensma sales.
  • J
    JT
    Happy days are here again!
  • K
    Kroptie
    The analysts have projected peak Zolgensma sales at $5 billion. RGNGX will get peak royalty rate of 13%. This equates to 13%x $5 billion= $650 million in net revenue or $17.06 a share in eps or royalties to RGNX every year.. This combined with $10 a share in cash and very profitable RGX 314 blockbuster multibillion dollar gene therapy, makes this stock a sleeper and sleeping giant that will trade at over $100 a share on its own. Novartis is rumored to Pay $90 share now.
  • K
    Kroptie
    Artificially depressed. Will run up. Great fundamnetals
    Owns 100 AAV gene library worth > 3 Billion. Licenses out to 20 companies
    Gets royalties from 20 companies
    Zolgensma royalties go up to 13%
    Projected royalties are very large
    20,000 babies at $1.8 million per patients x 13% royalty= $4.6 billion in projected royalties to RGNX from Novartis
    This is $4.6 billion/38 million shares=$100+ a share in royalties to RGNX on Zolgensma payable to RGNX from Novartis

    Share price is way behind value of stock.

    RGX 314 is blockbuster potential for wet AMD
    1 million wet AMD patients at $100,000 per patient= $100 billion If just treat 15 % pf patients thi is $15 billion to RGNX in revenue just from RGX 314
    This obviates treatment of 16 painful eye injections a year. Patients improve sight by 11-23 letters on eye chart which means many can drive instead of sitting waiting for people to drive them.

    This is a $100+ stock. Shorts have artifically depressed sp. Wednesday everyone breaks out sp to high 30-s. Takeover by Novartis will be $90 a share with RGNX has 10 a share in cash.
  • J
    JT
    Attached is a 10/1/20 Novartis/Zolgensma update that indicates that Zolgensma treatments are expanding rapidly. Regenxbio is listed (near the end) and treatments are now approved in the U.S., Japan, Europe and Brazil. Novartis Gene Therapies is pursuing registration in close to three dozen countries with regulatory decisions anticipated in Switzerland, Canada, Israel, Australia, and South Korea in late-2020 or early 2021. That could make big Royalty and milestone pmts to RGNX.
    https://www.novartis.com/news/media-releases/zolgensma-data-including-patients-more-severe-sma-baseline-further-demonstrate-therapeutic-benefit-including-prolonged-event-free-survival-increased-motor
  • K
    Kroptie
    we are at 11% royalty on Zolgensma with NVS. 1.NVS owes 500 million in royalties
    2.RGNX owns 100 aav gene library with 20 royalty partnerships
    3. RGX 314 is $10 Billion gene therapy for wet AMD
    4. 4 other major Billion dollar programs
    5. Cash +marketable securities= $650 million or $17.56 a share, more than 60% of market cap
    6. Miniscule market cap 1.1 Billion
    7. Vanguard, Blackrock, and State Street owns 1/3 of co.
    8. 5 million shares short cant cover with tiny float
    9. Only 37 million shares out.-not dilutors
    10. Insiders own 1/3 of co
    11. Proven therapy.
    12. 0 debt
    13. Royalties in 2 years will be $7-10 a share on Zolgensma which costs $2.1 billion per patient
    14. RGNX gets over $225,000 a patient at this tiered level of Zolgensma sales
  • J
    JT
    Regenxbio announced this morning that it will receive a milestone payment of $80.0 million from Novartis AG based upon the achievement of $1.0 billion in cumulative net sales of Zolgensma. REGENXBIO expects to recognize this revenue in the third quarter of 2020. The announcement also stated REGENXBIO has earned more than $140.0 million in revenues from royalties and commercial milestone payments related to Zolgensma through the third quarter of 2020. You can read the entire news release on the RGNX website.
  • K
    Kroptie
    Novartis owes up to 13% royalties on Zolgensma. It owes 500 million total in milestones too. At current market cap of 1.1 Billion it will make extremely likely to acquire co. Then it gets $650 million in cash and marketable securities, 100 AAV gene library, 20 partnerships for royalties, RGX 314 $10 billion drug, 4 other programs of drugs, all for free, It will pay premium that could reach $85-90 a share which is highest price in last 2 years. This is most proprietary gene therapy in world.
  • B
    Bill
    Thanks for the discount this morning!
  • K
    Kroptie
    Zolgensma royalties topped 1 billion. Royalty rate is now 9% from 6%. . Will have ongoing royalties at over $90 million a year. RGX314 is doing very well in trials with improvements of 11-23 letters on a snellen chart.
  • M
    Mark
    I am long and all your information is optimistic. But please tell me if it is so obvious they are undervalued, why is this stock back to a 3 year low with a steady decline over the last 6-12 months??
  • A
    Allen
    FOR MR. KROPTIEI'm a long time shareholder and definitely know the potential. Unfortunately, we need more time - the royalties need to grow from multiple sources and let's see how WET-AMD progresses. I firmly believe RGNX can be a $300 stock ($10B market cap) or more with ease, but we are a while away.I'm writing to ask what is wrong with you? You seem obsessed and post like a madman every few days! Do you believe that the more you post, the more the stock shall rise? Just gather your facts in a little notebook and maybe post here once every other month. I'm really getting sick of seeing "Kroptie" then a bunch of posts by a lunatic. Lots of great energy you have, but holy #$%$ take a pill!
  • K
    Kroptie
    This quarter includes over $141 million in royalties and milestones or $4 a share eps